MannKind (NASDAQ:MNKD – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Earnings & Valuation
This table compares MannKind and Silo Pharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MannKind | $313.79 million | 4.86 | $27.59 million | $0.10 | 49.70 |
| Silo Pharma | $70,000.00 | 69.19 | -$4.39 million | ($0.95) | -0.38 |
Risk and Volatility
MannKind has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.
Insider & Institutional Ownership
49.5% of MannKind shares are held by institutional investors. Comparatively, 5.6% of Silo Pharma shares are held by institutional investors. 2.7% of MannKind shares are held by insiders. Comparatively, 2.2% of Silo Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares MannKind and Silo Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MannKind | 10.87% | -32.60% | 7.81% |
| Silo Pharma | -7,050.00% | -107.03% | -77.06% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for MannKind and Silo Pharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MannKind | 0 | 2 | 6 | 1 | 2.89 |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
MannKind presently has a consensus target price of $10.21, indicating a potential upside of 105.52%. Given MannKind’s stronger consensus rating and higher probable upside, equities analysts clearly believe MannKind is more favorable than Silo Pharma.
Summary
MannKind beats Silo Pharma on 14 of the 15 factors compared between the two stocks.
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.
